228246-76-2

Basic information

• Product Name: (S)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE
• Synonyms: (S)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE
• CAS NO: 228246-76-2
• Molecular Formula: C17H17NO
• Molecular Weight: 251.327
• Mol File: 228246-76-2.mol

Chemical Properties

• Boiling Point: 447.741°C at 760 mmHg
• Flash Point: 210.969°C
• Appearance: /
• Density: 1.241g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.679
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE(228246-76-2)
• EPA Substance Registry System: (S)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE(228246-76-2)

Safety Data

• Hazardous Substances Data: 228246-76-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE is used as a potential drug candidate for the treatment of neurological disorders such as Alzheimer's disease and Parkinson's disease. Its pharmacological activities make it a promising agent for further research and development in this field.
Used in Pain Management:
(S)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE is used as a potential analgesic agent, indicating its potential use in pain management and treatment of various conditions that involve pain as a symptom.
Used in Anti-Inflammatory Applications:
(S)-1-(1,2-DIHYDROACENAPHTHYLEN-1-YL)PIPERIDIN-4-ONE is used as a potential anti-inflammatory agent, suggesting its possible application in the treatment of inflammatory conditions and diseases.

InChI:InChI=1/C17H17NO/c19-14-7-9-18(10-8-14)16-11-13-5-1-3-12-4-2-6-15(16)17(12)13/h1-6,16H,7-11H2/t16-/m0/s1

Upstream product

• 77542-18-8 1-methyl-1-ethyl-4-oxopiperidinium iodide 
• 228246-74-0 (S)-1-Acenaphthylamine 
• 6306-07-6 (R)-1,2-dihydroacenaphthylen-1-ol 

Downstream Products

• 228246-78-4 (S)-4-phenylamino-1-(acenaphthen-1-yl)-piperidine-4-carbonitrile 

Relevant articles and documents

1,3,8-triazaspiro[4,5]decan-4-one derivatives

The present invention relates to compounds of the formula wherein R1 and R2 are each independently hydrogen, lower alkyl, lower alkoxy or halogen; R3 is phenyl, which is unsubstituted or substituted by lower alkyl, CF3, lower alkoxy or halogen; R4 is hydrogen, lower alkyl, lower alkenyl, -C(O)-lower alkyl, -C(O)-phenyl, lower alkyl-C(O)-phenyl, lower alkylene-C(O)O-lower alkyl, lower alkantriyl-di-C(O)O-lower alkyl, hydroxy-lower alkyl, lower alkyl-O-lower alkyl, lower alkyl-CH(OH)CF3, phenyl or benzyl, R5 and R6 are each independently hydrogen, phenyl, lower alkyl or di-lower alkyl or R5 and R6 together with the carbon atoms to which they are bound form a phenyl ring, or R5 and one of R1 or R2 together with the carbon atoms to which they are bound form a saturated or unsaturated 6 membered ring, A is a 4-7 membered saturated ring, their racemates and the enantiomers thereof, and the pharmaceutically acceptable acid addition salts thereof which are agonists and/or antagonists of the OFQ receptor.

8-Acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as orphanin FQ receptor agonists

A series of 8-acenaphthen-1-yl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4- one derivatives 1 was studied with respect to the binding affinity for the orphanin FQ (OFQ) and opioid (μ, κ, δ) receptors. The influence of stereochemistry as well as the substitution pattern of the phenyl-ring in position 1 on the affinity for the orphanin FQ receptor and selectivity to opioid (μ, κ, δ) receptors is discussed. The most interesting compound 1c was tested for its anxiolytic-like properties in vivo.